Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

119.48 +1.09 (+0.92%)
Streaming Delayed Price Updated: 10:02 AM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA 
From Biogen Inc.
Via GlobeNewswire
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
Exposures Political
Peering Into Biogen's Recent Short Interest
Via Benzinga
17 Analysts Assess Biogen: What You Need To Know
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
FDA reviews Eisai and Biogen's BLA for Leqembi SC-AI, targeting Alzheimer's treatment with home-based weekly autoinjector dosing. 
Via Benzinga
Exposures Product Safety
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option 
From Biogen Inc.
Via GlobeNewswire
Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In
The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression. 
Via Stocktwits
Exposures Product Safety
Assessing Biogen: Insights From 19 Financial Analysts
Via Benzinga
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression. 
Via Benzinga
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression. 
Via Benzinga
Enduring Truths for Investors Both New and Seasoned
Via The Motley Fool
Grid Expansion; Beaten Blues
While the mega-caps seem to get all the attention these days, there's 1,000s of stocks out there worth researching. 
Via Talk Markets
Topics Stocks / Equities
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025. 
Via Benzinga
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
One analyst says the six-month study was too short and the benefits could appear over time. 
Via Investor's Business Daily
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
Via The Motley Fool
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
Large-Cap Stocks In Trouble - Saturday, Dec. 21
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
Topics Stocks / Equities
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Super Micro Computer Teeters On Edge Of Nasdaq 100: Can xAI, Nvidia Help Stabilize Trajectory?
Super Micro faces potential delisting from Nasdaq 100 Index due to underperformance and auditing scandal. Uncertainty surrounds its future. 
Via Benzinga
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
Jefferies downgrades Biogen with a reduced price target, citing pipeline setbacks, slow Leqembi sales, and challenges from declining Ocrevus royalties. 
Via Benzinga
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over
Via The Motley Fool
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024. 
Via Benzinga
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.